Review of Checkpoint Inhibitor Immunotherapy in Neuroendocrine Tumor of Prostate and Our Experience in 2 Cases

• Main Authors: Akriti Pokhrel MD (Author), Kiron Nair MD (Author), Vijay Jaswani MD (Author), Muhammad Salyana MD (Author), Unni Mooppan MD (Author), Jen C. Wang MD (Author)
• Format: Book
• Published: SAGE Publishing, 2022-04-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Neuroendocrine prostate cancer (NEPC) is a rare entity. De novo NEPC is extremely rare; other cases are usually adenocarcinoma previously treated with hormonal therapies transforming to NEPC. Most of the cases are metastatic at diagnosis and regardless of the histology types, the prognosis is poor....